Mainstream news outlets have finally begun to cover DMAA with stories yesterday in the New York Times and FoxNews.com and a blog post from the Wall Street Journal. Trade press has addressed the DMAA issue for some time (see Nutrition Business Journal’s initial coverage), and headlines have been hitting faster since December, when the U.S. Military recalled all DMAA-containing products from exchange stores after the ingredient was found in the blood of two soldiers who died last year during training.
Large-scale coverage of this issue caps off what has turned into a very intense news week for the supplement industry. First, industry gave an inflamed response to Dr. Pieter Cohen’s editorial in the New England Journal of Medicine. Cohen (who is quoted in the New York Times article on DMAA) called for greater regulation of the supplement industry and tighter strictures for FDA’s already burdensome New Dietary Ingredient (NDI) guidance, igniting the ire of industry leaders.
Then, news broke of an unsuccessful meeting between Senators Hatch and Harkin—co-creators of the Dietary Supplements Health & Education Act (DSHEA)—and Dr. Daniel Fabricant, head of the FDA’s Division of Dietary Supplements. Hatch and Harkin called for the withdrawal of the guidance, pointing out its conflict with the intent of DSHEA, which they had written. FDA rejected the request for withdrawal, and it looks like the agency may go ahead with the document as written.
Now, with DMAA making headlines, FDA has a bit more leverage on the supplement industry and reason to stand firm with NDI guidance.
What happens next? Tell us in the comments.